ArticleJournal of biochemical and molecular toxicology2025
Protective Effects of Phoenixin-14 Administration Against Renal Ischemia/Reperfusion Injury in Rats.
Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Enhanced Discrimination of Coronary Artery Disease Severity by Circulating Phoenixin-14: Evidence from a Clinical Laboratory Study.International journal of molecular sciences · 2026Article
- Renoprotective Potential of Nateglinide in an Acute Kidney Injury Model.International journal of molecular sciences · 2026Article
- Serum phoenixin-14 levels in chronic kidney disease and hemodialysis patients: a cross-sectional study.Frontiers in medicine · 2026Article
- Renoprotective mechanisms of bioconverted wild-simulated ginseng: mitigating oxidative stress, inflammation, and apoptosis to protect against ischemic renal injury via Nrf2/HO-1/NF-κB/caspase-3 signaling.Journal of ginseng research · 2026Article
- Phoenixin-14 ameliorates ovarian morphology in a DHEA-induced rat model of PCOS.Reproduction & fertility · 2026Article
- Asprosin protects against ischemia/reperfusion-induced kidney injury in mice.Journal of molecular histology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phoenixin (PNX), identified in the rat hypothalamus in 2013, has two bioactive isoforms with 14 and 20 amino acids. Initially studied for its role in reproductive regulation, research has since shown that PNX also prevents visceral pain, enhances memory, and aids heart tissue recovery. However, its role in kidney tissue remains unclear. Due to its antioxidant properties, PNX may help reduce oxidative stress and cellular damage in organs. This study was designed to determine the potential protective effects of Phoenixin-14 (PNX-14) against renal ischemia/reperfusion (I/R)-induced injury in rats. 40 male Wistar Albino rats were divided into four groups: Control, I/R, PNX-14 (50 µg/kg), and PNX-14 (100 µg/kg) (n = 10). All groups except the control group underwent 45 min of bilateral ischemia followed by 24 h of reperfusion. PNX-14 (50 and 100 μg/kg, intraperitoneally) was administered 1 h before induction of ischemia. Both doses of PNX-14 reduced the levels of acute kidney injury markers (blood urea nitrogen and creatinine) in blood tissue (p < 0.05). PNX-14 increased the activity of antioxidant enzymes (superoxide dismutase and catalase) and the levels of glutathione, while reducing malondialdehyde (p < 0.05). Histological evaluation of the I/R group revealed significant histopathological findings, and it was found that PNX-14 administration improved these histological damages (p < 0.05). These results suggest that PNX-14 provides protection against renal injury induced by I/R. After further studies, PNX-14 may be a new therapeutic strategy to prevent renal I/R injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.